Acclinate Logo
Talk to Our Team

Birmingham, AL ( April 18, 2022) - Acclinate, a leading digital health company, announced the appointment of Camille Pope, PharmD as Chief Medical Lead. She brings 14+ years of pharmaceutical industry experience to the company. In this role, Camille will oversee all medical and scientific communication between community members and pharmaceutical industry/healthcare partners. She will also contribute strategic market intelligence to help further develop Acclinate’s platform and services.  

“Acclinate has made great strides in building a world-class team and developing innovative technologies to drive sustained community engagement leading to greater clinical trial diversity," said Dr. Pope. "I'm thrilled to join the Acclinate team and work with such a talented group of individuals on our quest to achieve health equity through inclusive research".

With experience in medical affairs across several therapeutic areas, Camille is a proven pharmaceutical industry leader with extensive drug launch experience. Before joining Acclinate, Camille served as the US Medical Lead for Prostate Cancer at AstraZeneca and as a Senior MedicalScience Liaison for Hepatitis C & HIV at Abbvie. She was recognized for her leadership by AstraZeneca's Rising Leaders Program and the She-Suite BrandLeadership Institute.

"Camille is a key leadership addition to our team," said Del Smith, CEO and co-founder of Acclinate. "Her extensive domain knowledge and demonstrated passion for health equity will be a tremendous asset as we continue to scale."

As an experienced healthcare professional with demonstrated expertise in diversity and inclusion, Camille is enthusiastic about fostering diverse talent and striving for health equity. She has championed several projects to address clinical trial diversity gaps and established  AstraZeneca's US Medical Oncology Inclusion& Diversity Talent Recruitment Workstream, which led to new partnerships with Howard University’s College of Pharmacy and the Tom Joyner Foundation.

"Acclinate continues to break down barriers for communities of color in the clinical trial space and create a more robust and efficient process for researchers and sponsors," said CDO and co-founder Tiffany Whitlow. "Leading the charge in diversifying clinical trials requires a top-tier team that exhibits leadership. I look forward to working with Camille to implement innovative strategies that will help us scale and enhance our offering.

Camille holds a Doctor of Pharmacy degree from Florida Agricultural and Mechanical University. She completed a Post-Doctoral Medical Strategy Fellowship with Bristol-Myers Squibb/Rutgers Institute for Pharmaceutical Industry Fellowships. Camille is currently earning her graduate certificate in Health Disparities Research from the University of Illinois Chicago.

_____________

About Acclinate™

Acclinate™ is a Birmingham-based digital health company helping pharmaceutical companies and healthcare organizations access and engage communities of color so that research is more inclusive.

Recent Posts

For CROs, Clinical Trial Marketing Isn’t Just Support—It Is Business Development
4 Min Read

At its core, clinical research is about advancing treatments that change lives—for individuals, families, and entire communities. But those treatments...

Read More
Engaging Black and Brown Communities in Research
6 Min Read

Key Takeaways and Learnings Long-term relationship building delivers measurable results. Culturally responsive research practices require representati...

Read More
Health Tech for Inclusive Research Starts with Representation
5 Min Read

Key Takeaways and Learnings Health tech for inclusive research must be built with representation at the forefront—from design to deployment. Exclusion...

Read More
Keep Personalization Alive: Building Scalable Tech That Serves Every Community
4 Min Read

When I think about the role of technology in healthcare, I feel both excited and cautious. Excited, because scaling technology means we can reach more...

Read More
Improve Diversity in Clinical Trials Without Slowing Progress
4 Min Read

Key Takeaways and Learnings The belief that representation slows clinical trials is outdated—early inclusion strategies often speed them up. Retention...

Read More
Why Diverse Clinical Trials Yield Smarter, Safer Science
4 Min Read

Key Takeaways and Learnings Diverse clinical trials yield smarter, safer science by making results more generalizable and interventions more effective...

Read More
Turning Data Into Direction: Business Intelligence as a Catalyst for Inclusive Research
3 Min Read

I learned to respect business intelligence (BI) in hospitals and health systems, where every decision felt urgent and the stakes were always high. In ...

Read More
6 Proven Strategies for Representative Trial Recruitment
5 Min Read

Key Takeaways and Learnings One-size-fits-all efforts don’t result in inclusive participant outreach plans that work. Predictive analytics, community ...

Read More
Reduce Recruitment Risk in Pharma Through Representation
4 Min Read

Key Takeaways and Learnings Underrepresentation slows recruitment, increases dropout risk, and weakens data reliability. Proactive inclusion strategie...

Read More